Surprisingly Strong Momentum: Why Analysts See +25% Upside

At first glance, this company hardly resembles a high-growth story. A long-time specialist in spinal implants, surgical robotics and technologies for musculoskeletal disorders has traditionally been viewed as a steady, slow-moving player in the med-tech sector. But the last two years have rewritten that narrative. The company has entered one of the most explosive growth cycles in its history: revenue and assets are accelerating, margins remain elevated, and analysts have been forced to revise their models upward. Such synchronized strength is rare — and it’s the reason investors are suddenly paying much closer attention.

Behind the scenes stands a powerful combination of factors: rapid expansion of the product portfolio, strong traction in surgical robotics, rising demand for orthopedic solutions, and one transformative acquisition that shifted the entire scale of the business. Even more intriguingly, the stock still trades below its historical highs, while analysts now estimate…